Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Liquidia Corporation filings document a Delaware biopharmaceutical issuer reporting on YUTREPIA commercialization, treprostinil products and pulmonary hypertension programs. Form 8-K reports furnish quarterly and annual financial results, Regulation FD disclosures, corporate updates and investor presentation materials tied to PAH, PH-ILD, PRINT® Technology and the company’s product portfolio.
The filing record also covers governance and capital-market disclosure subjects, including definitive proxy materials, officer appointments and material definitive agreements. Recent agreement disclosures include the Liquidia Technologies licensing arrangement with Vectura for L606 and a nebulizer device in hypertension and interstitial lung disease treatment fields.
Liquidia (LQDA): CEO and Director Roger Jeffs reported insider transactions. On 10/10/2025, 13,834 shares of common stock were acquired via the conversion of performance stock units at $0. On 10/13/2025, 20,261 shares were sold at $23.41 under a Rule 10b5-1 plan adopted on December 15, 2023.
After these transactions, direct holdings were 1,032,973 shares. Indirect holdings included 46,595 shares held by the Roger A. Jeffs Living Trust and 1,541,667 shares held by Serendipity BioPharma LLC, over which he has sole voting and dispositive power. The sale was to cover taxes associated with RSU and PSU settlements.
Liquidia (LQDA) reported insider activity by its Chief Business Officer. On 10/10/2025, the officer settled equity awards, converting 3,906 RSUs and 2,474 PSUs into common stock. On 10/13/2025, 3,670 shares were sold at $23.41 under a Rule 10b5-1 plan to cover taxes tied to those settlements. Following these transactions, the officer beneficially owned 175,690 common shares, held directly. RSUs and PSUs convert one-for-one into common stock, with remaining unvested awards continuing on their stated vesting schedules.
Liquidia (LQDA) reported an insider transaction by Chief Human Resource Officer Sarah Krepp. On 10/13/2025, she sold 1,691 shares of common stock at $23.41 per share under a Rule 10b5-1 plan adopted on December 15, 2023. The sale covered taxes tied to RSU settlements from awards granted on January 11, 2024 and July 1, 2024.
After the trade, she beneficially owned 141,439 shares. Her holdings include unvested RSUs from 2024 and 2025 grants and 5,312 shares acquired under the 2020 ESPP.
Liquidia (LQDA) reported an insider transaction by its Chief Accounting Officer. On 10/13/2025, the officer sold 1,238 shares of common stock at $23.41 per share, coded “S,” pursuant to a Rule 10b5-1 plan adopted on December 15, 2023. The filing states the sale was to cover taxes tied to the settlement of restricted stock units granted on January 11, 2024.
After the transaction, the officer beneficially owned 185,411 shares, held directly. Holdings include unvested RSUs from prior grants and 11,869 shares acquired under the company’s 2020 Employee Stock Purchase Plan.
Liquidia Corp. (LQDA) insider activity: Chief Medical Officer Dr. Rajeev Saggar reported a PSU conversion and a tax-related sale. On 10/10/2025, 3,530 performance stock units converted into common stock on a one-for-one basis (code M). On 10/13/2025, 5,327 shares were sold at $23.41 (code S) pursuant to a Rule 10b5-1 plan adopted on December 15, 2023.
Following these transactions, the reporting person beneficially owns 247,930 shares, held directly. The sale was disclosed as covering taxes tied to the settlement of RSUs and PSUs initially granted on January 11, 2023 and January 11, 2024. The officer’s role is listed as Chief Medical Officer.
Liquidia Corp (LQDA) Chief Commercial Officer Scott Moomaw reported insider transactions. On 10/10/2025, 3,108 common shares were acquired upon settlement of performance stock units at $0 per unit. On 10/13/2025, 4,900 shares were sold at $23.41 pursuant to a Rule 10b5-1 plan; the filing notes the sale covered taxes related to prior RSU/PSU settlements.
Following these transactions, he beneficially owned 153,462 common shares directly and held 27,969 unvested RSUs.
Liquidia (LQDA) officer Michael Kaseta (CFO and COO) reported a Form 4 showing equity settlement and a tax-related sale. On 10/10/2025, he acquired 5,828 shares of common stock upon the conversion of performance stock units, which convert one-for-one into common stock. On 10/13/2025, he sold 11,630 shares at $23.41 per share pursuant to a Rule 10b5-1 plan.
The filing states the sale was made to cover taxes from the settlement of previously granted RSUs and PSUs. Following the transactions, Kaseta beneficially owned 352,646 shares directly. The derivative table lists 52,453 derivative securities beneficially owned after the reported transactions.
Liquidia (LQDA): Form 4 insider activity — The company’s General Counsel reported a conversion of performance stock units and a tax-related sale. On 10/10/2025, 3,758 PSUs converted into an equal number of common shares. On 10/13/2025, 7,839 common shares were sold at $23.41, effected under a Rule 10b5-1 plan adopted on 12/15/2023 and to cover taxes associated with prior RSU and PSU settlements.
Following these transactions, the reporting person directly held 576,017 common shares and had 33,826 derivative securities (PSUs) beneficially owned. An additional 14,500 shares are held indirectly by a spouse. PSU and RSU grants vest on stated schedules, with one-for-one PSU conversion into common stock.
Amendment corrects previously omitted indirect holdings: Dr. Stephen M. Bloch, a director of Liquidia Corp (LQDA), amended a prior Form 4 to include 2,917,169 shares of common stock reported as indirectly held through Canaan VIII L.P. The filing states these shares are held by Canaan LP, whose sole general partner is Canaan Partners VIII LLC; investment and voting decisions are made by the managers of Canaan LLC. The Reporting Person disclaims beneficial ownership except for any pecuniary interest from his LLC interest. No derivative securities are reported in this amendment.
Amendment corrects previously omitted indirect holdings: Dr. Stephen M. Bloch, a director of Liquidia Corp (LQDA), amended a prior Form 4 to include 2,917,169 shares of common stock reported as indirectly held through Canaan VIII L.P. The filing states these shares are held by Canaan LP, whose sole general partner is Canaan Partners VIII LLC; investment and voting decisions are made by the managers of Canaan LLC. The Reporting Person disclaims beneficial ownership except for any pecuniary interest from his LLC interest. No derivative securities are reported in this amendment.
Raman Singh, a director of Liquidia Corp (LQDA), exercised stock options and sold a portion of the resulting shares on 09/15/2025. He exercised a non-qualified option with a $2.51 strike to acquire 25,524 shares and a separate option with a $2.59 strike to acquire 20,000 shares. On the same date he sold 45,524 shares at a volume-weighted average price of $25.81, leaving him with beneficial ownership of 31,255 shares. The filing also discloses 18,396 restricted stock units granted on June 17, 2025 that had not vested as of the report date.
Raman Singh, a director of Liquidia Corp (LQDA), exercised stock options and sold a portion of the resulting shares on 09/15/2025. He exercised a non-qualified option with a $2.51 strike to acquire 25,524 shares and a separate option with a $2.59 strike to acquire 20,000 shares. On the same date he sold 45,524 shares at a volume-weighted average price of $25.81, leaving him with beneficial ownership of 31,255 shares. The filing also discloses 18,396 restricted stock units granted on June 17, 2025 that had not vested as of the report date.